Cumberland Pharmaceuticals vs IM Cannabis
Cumberland Pharmaceuticals and IM Cannabis are similar in size: $44.5m and $39.2m of revenue in their latest fiscal years. Cumberland Pharmaceuticals grew faster (17.6% against -0.7%). Cumberland Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -6.4% against -20.7%.
| Latest fiscal year | Cumberland PharmaceuticalsCPIX, 2025 | IM CannabisIMCC, 2025 |
|---|---|---|
| Revenue | $44.5m | $39.2m |
| Revenue growth | 17.6% | -0.7% |
| Net income | −$2.8m | −$8.1m |
| Operating margin | -6.3% | -21.2% |
| Net margin | -6.4% | -20.7% |
| Return on equity | -11.9% | — |
| Free cash flow | $4.8m | $3.4m |
| Cash | $11.4m | $2.0m |
| Total debt | $5.2m | $11.8m |
| Debt to equity | 21.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $263,478 | — |
| Employees | 93 | — |
| Market value | $63.2m | $4.4m |
| Price vs our value range | Above our value range | — |
| Moat score | 57 (Moderate) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |